Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
22-2
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
22-2
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Index of Authors
Author #67287
advertisement
Wallukat G
16
Showing records 1 to 16 |
Display all abstracts from
Wallukat G
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Hohberger B
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Hohberger B
PLoS ONE
2021; 16: e0249202
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Wörn M
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Hosari S; Hosari S
PLoS ONE
2021; 16: e0249202
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Lämmer R
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Wallukat G
PLoS ONE
2021; 16: e0249202
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Mahajan A
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Kunze R; Krebs J
PLoS ONE
2021; 16: e0249202
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Mardin C
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Müller M
PLoS ONE
2021; 16: e0249202
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Schötzer-Schrehardt U; Kunze R
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Hennig T
PLoS ONE
2021; 16: e0249202
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Herrmann M
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Lämmer R
PLoS ONE
2021; 16: e0249202
94457
Agonistic 2-Adrenergic Receptor Autoantibodies Characterize the Aqueous Humor of Patients With Primary and Secondary Open-Angle Glaucoma
Wallukat G
Frontiers in immunology
2021; 12: 550236
94314
Agonistic autoantibodies against ß2-adrenergic receptor influence retinal microcirculation in glaucoma suspects and patients
Horn F; Muñoz LE; Herrmann M; Mardin C
PLoS ONE
2021; 16: e0249202
Issue
22-2
Table of Contents
Editor's Selection
PDF
EPUB
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept